MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

Search

Viking Therapeutics Inc

Closed

SectorHealthcare

24.14 -6

Overview

Share price change

24h

Current

Min

24.01

Max

25.86

Key metrics

By Trading Economics

Income

-10M

-35M

EPS

-0.32

Employees

36

EBITDA

-9.6M

-46M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+290.38% upside

Dividends

By Dow Jones

Next Earnings

23 Apr 2025

Market Stats

By TradingEconomics

Market Cap

-375M

2.9B

Previous open

30.14

Previous close

24.14

News Sentiment

By Acuity

50%

50%

180 / 386 Healthcare

Technical Score

By Trading Central

Confidence

Strong Bearish Evidence

Viking Therapeutics Inc Chart

Past performance is not a reliable indicator of future results.

Related News

7 Feb 2025, 10:30 UTC

Top News

The Drug Industry Is Having Its Own DeepSeek Moment -- Heard on the Street -- WSJ

23 Dec 2024, 15:04 UTC

Top News

Eli Lilly, Novo Nordisk Stocks Rise. One of These Obesity Drugmakers Just Hit a Landmark. -- Barrons.com

13 Dec 2024, 14:53 UTC

Top News

Ozempic Works on Kidney Disease, Regulator Says. Why Novo Nordisk Stock Is Falling. -- Barrons.com

4 Nov 2024, 12:22 UTC

Top News

Viking Therapeutics Jumps On Latest Obesity Drug Data -- IBD

4 Nov 2024, 12:00 UTC

Top News

Big Pharma's Obesity Bonanza Faces New Tests -- Heard on the Street -- WSJ

4 Nov 2024, 10:11 UTC

Hot Stocks

Stock to Watch Monday: Trump Media, Viking Therapeutics, Nvidia, Intel -- WSJ

4 Oct 2024, 12:01 UTC

Top News

As Weight-Loss Drugs Battle, Upstart Viking -2-

4 Oct 2024, 12:01 UTC

Top News

As Weight-Loss Drugs Battle, Upstart Viking Therapeutics Threatens Eli Lilly, Novo Nordisk, Pfizer -- IBD

20 Sept 2024, 13:55 UTC

Top News

Update: Novo's Wegovy Gets Backing of a Regulator for Heart Condition Treatment. FDA Could Be Next. -- Barrons.com

25 Jul 2024, 15:03 UTC

Earnings

Viking Stock Jumps After Company Speeds Development Its Weight-Loss Pill -- Barrons.com

Peer Comparison

Price change

Viking Therapeutics Inc Forecast

Price Target

By TipRanks

290.38% upside

12 Months Forecast

Average 100.25 USD  290.38%

High 164 USD

Low 38 USD

Based on 16 Wall Street analysts offering 12 month price targets forViking Therapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

16 ratings

15

Buy

1

Hold

0

Sell

Technical Score

By Trading Central

23.27 / 26.09Support & Resistance

Short Term

Strong Bearish Evidence

Intermediate Term

Bearish Evidence

Long Term

Bearish Evidence

Sentiment

By Acuity

180 / 386 Healthcare

News Sentiment

Neutral

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Viking Therapeutics Inc

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.